Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-126 · 5 trials · 4 indications
vital signs, electrocardiogram (ECG), neurological examination, laboratory tests, number of subjects with adverse events, Columbia-Suicide Severity Rating Scale (C-SSRS)
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | ABT-126 Low Dose |
| 2 | EXPERIMENTAL | ABT-126 High Dose |
| 3 | EXPERIMENTAL | Placebo for ABT-126 |
| 20mg of ABT-126 QD | ACTIVE_COMPARATOR | 20 mg of ABT-126 QD for 10 days |
| 30mg and 45mg ABT-126 QD | ACTIVE_COMPARATOR | 30 mg and 45mg of ABT-126 QD for 21 days |
| Name | Type | Description |
|---|---|---|
| ABT-126 | DRUG | Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days. |
| Placebo | DRUG | Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days. |
| Placebo for ABT-126 | DRUG | Matching Placebo for Arms 1 \& 2 |
Inclusion Criteria 1. Male or female and age between 55 and 90 years, inclusive. 2. The subject meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease (AD). 3....
Top 20 of 24 competitors
ABT-126 is an investigational small molecule being studied in neurology for Alzheimer's disease, schizophrenia, and in healthy volunteers. It has been evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics. ABT-126 is not approved and remains in clinical development.
ABT-126 is being developed by Abbott Laboratories, traded under the ticker ABT. The company has sponsored Phase 1 clinical trials of the drug in the United States.
ABT-126 is in Phase 1 clinical development. All completed trials for the drug are Phase 1 studies, and it is not FDA approved. The drug remains investigational.
ABT-126 has completed four Phase 1 trials: NCT00867399 in elderly with Alzheimer's disease, NCT00912431 in healthy volunteers, NCT01043458 in schizophrenia, and NCT01482845 in Alzheimer's disease. All were conducted in the United States.
No alternative names for ABT-126 have been disclosed. The drug is referred to solely as ABT-126 in clinical trial records.
ABT-126 is an investigational drug that has completed Phase 1 trials. It is not approved for any use. The trials were randomized, double-blind, and controlled, but no later-phase studies are listed.